Proteomics International Laboratories Overview
- Year Founded
-
2001
- Status
-
Public
- Stock Symbol
-
PIQ
- Investments
-
1
- Share Price
-
$0.23
- (As of Friday Closing)
Proteomics International Laboratories General Information
Description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
Contact Information
Website
www.proteomics.com.auCorporate Office
- Post Office Box 3008
- QEII Medical Centre 6 Verdun Street
- Nedlands, Western Australia 6009
- Australia
Corporate Office
- Post Office Box 3008
- QEII Medical Centre 6 Verdun Street
- Nedlands, Western Australia 6009
- Australia
Proteomics International Laboratories Timeline
Proteomics International Laboratories Stock Performance
As of 20-Jun-2025, Proteomics International Laboratories’s stock price is $0.23. Its current market cap is $38.2M with 164M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.23 | $0.23 | $0.22 - $0.76 | $38.2M | 164M | 197K |
Proteomics International Laboratories Financials Summary
As of 31-Mar-2025, Proteomics International Laboratories has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
|---|---|---|---|---|
| EV | 37,879 | 73,165 | 64,883 | 66,173 |
| Revenue | 585 | 491 | 1,079 | |
| EBITDA | (3,941) | (3,927) | (3,304) | |
| Net Income | (4,179) | (4,152) | (3,604) | |
| Total Assets | 7,269 | 6,669 | 3,712 | |
| Total Debt | 211 | 42 | 0 |
Proteomics International Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Proteomics International Laboratories Comparisons
Industry
Financing
Details
Proteomics International Laboratories Competitors (1)
One of Proteomics International Laboratories’s competitors is Evestra, a Venture Capital-Backed company based in Schertz, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Evestra | Venture Capital-Backed | Schertz, TX |
Proteomics International Laboratories Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Proteomics International Laboratories Patents
Proteomics International Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024900353-A0 | Airway disease biomarkers | Pending | 14-Feb-2024 | ||
| AU-2023900328-A0 | Airway disease biomarkers | Pending | 10-Feb-2023 | ||
| AU-2022900265-A0 | Airway disease biomarkers | Pending | 09-Feb-2022 | ||
| AU-2020900805-A0 | Endometriosis biomarkers | Pending | 16-Mar-2020 | ||
| AU-2021237128-A1 | Endometriosis biomarkers | Pending | 16-Mar-2020 | G01N33/689 |
Proteomics International Laboratories Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Proteomics International Laboratories Investments (1)
Proteomics International Laboratories’s most recent deal was a Secondary Transaction - Private with Agilex Biolabs for . The deal was made on 05-Mar-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Agilex Biolabs | 05-Mar-2018 | Secondary Transaction - Private | Other Pharmaceuticals and Biotechnology |
Proteomics International Laboratories Exits (1)
Proteomics International Laboratories’s most recent exit was on 05-Mar-2018 from Agilex Biolabs. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Agilex Biolabs | 05-Mar-2018 | Completed |
|
Proteomics International Laboratories FAQs
-
When was Proteomics International Laboratories founded?
Proteomics International Laboratories was founded in 2001.
-
Where is Proteomics International Laboratories headquartered?
Proteomics International Laboratories is headquartered in Nedlands, Australia.
-
What industry is Proteomics International Laboratories in?
Proteomics International Laboratories’s primary industry is Diagnostic Equipment.
-
Is Proteomics International Laboratories a private or public company?
Proteomics International Laboratories is a Public company.
-
What is Proteomics International Laboratories’s stock symbol?
The ticker symbol for Proteomics International Laboratories is PIQ.
-
What is the current stock price of Proteomics International Laboratories?
As of 20-Jun-2025 the stock price of Proteomics International Laboratories is $0.23.
-
What is the current market cap of Proteomics International Laboratories?
The current market capitalization of Proteomics International Laboratories is $38.2M.
-
Who are Proteomics International Laboratories’s competitors?
Evestra is a competitor of Proteomics International Laboratories.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
